A5044325195- Dementia and Cognitive Impairment Research
- Alzheimer's disease research and treatments
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Health Systems, Economic Evaluations, Quality of Life
- Statistical Methods in Clinical Trials
- CAR-T cell therapy research
- Intracerebral and Subarachnoid Hemorrhage Research
- Nutrition and Health in Aging
- Computational Drug Discovery Methods
- Health disparities and outcomes
- Cognitive Functions and Memory
- Functional Brain Connectivity Studies
- Nanowire Synthesis and Applications
- Nutritional Studies and Diet
- Stroke Rehabilitation and Recovery
- Frailty in Older Adults
- Glioma Diagnosis and Treatment
- Rheumatoid Arthritis Research and Therapies
- Tryptophan and brain disorders
- MRI in cancer diagnosis
- Neural and Behavioral Psychology Studies
- Immune responses and vaccinations
- Advanced Algebra and Geometry
- Neuroinflammation and Neurodegeneration Mechanisms
- Neurobiology of Language and Bilingualism
Roche (Switzerland)
2019-2024
Biogen (Switzerland)
2024
Genedata (Switzerland)
2019
Massachusetts General Hospital
2008-2018
University of California, Irvine
2012-2017
Huntsman Cancer Institute
2015
University of California, Irvine Medical Center
2015
University of Utah
2015
UC Irvine Health
2014
Harvard University
2007-2008
<h3>Objective:</h3> The purpose of this study was to examine the role multiple pathologies in expression dementia oldest-old. <h3>Methods:</h3> A total 183 participants 90+ Study with longitudinal follow-up and autopsy were included clinical-pathologic investigation. Eight pathologic diagnoses (Alzheimer disease [AD], microinfarcts, hippocampal sclerosis, macroinfarcts, Lewy body disease, cerebral amyloid angiopathy, white matter others) dichotomized. We estimated odds relation each...
Abstract Introduction We investigated the association between age of onset hypertension and dementia risk in an oldest‐old cohort. Methods Participants are from The 90+ Study , a population‐based longitudinal study people aged who survivors Leisure World Cohort Study. estimated using self‐reported information Study, collected about 20 years earlier. A total 559 participants without were followed every 6 months for up to 10 years. Results 224 developed during follow‐up (mean = 2.8 years)....
Importance Data from 2 phase 3 studies of gantenerumab, GRADUATE I/II, and their open-label extensions represent a resource to further characterize amyloid-related imaging abnormalities (ARIA), including long-term sequelae. Objectives To describe the characteristics ARIA risk factors clinical consequences ARIA-edema (ARIA-E). Design, Setting, Participants Secondary data collection I/II randomized, double-blind, placebo-controlled, 116-week parallel-group extensions, PostGraduate, with up 210...
The goal of this study was to examine cross-sectional and longitudinal associations between cognitive performance beta amyloid (Aβ) load determined by florbetapir F18 positron emission tomography (PET) in nondemented oldest-old.Thirteen (normal or cognitively impaired nondemented) participants (median age, 94.2 years) from 90+ Study underwent florbetapir-PET scanning within 3 months baseline neuropsychological testing. Amyloid measured with a semi-automated quantitative analysis average...
To examine the cross-sectional relationship between physical performance and dementia in oldest old (those ≥ 90 years of age).Cross-sectional study.The 90+ Study is a population-based, longitudinal, epidemiologic study aging performed at University California, Irvine, from January 1, 2003, through November 30, 2009.A total 629 participants The were included study. mean age was 94 years, most (72.5%) women.All-cause dementia, based on Diagnostic Statistical Manual Mental Disorders (Fourth...
Glioblastoma multiforme (GBM) is the most aggressive and deadly form of adult brain cancer. Despite many attempts to identify potential therapies for this disease, including promising cancer immunotherapy approaches, it remains incurable. To address need improved persistence, expansion, optimal antitumor activity T-cells in glioma milieu, we have developed an EGFRvIII-specific third generation (G3-EGFRvIII) chimeric antigen receptor (CAR) that expresses both co-stimulatory factors CD28 OX40...
Objectives To examine the longitudinal association between physical performance and risk of dementia in individuals aged 90 older without dementia. Design Population‐based study. Settings The 90+ Study, Laguna Woods, California. Participants Men n = 176 women 402 from Study (n 578, mean age 93.3). At baseline, 54% participants were cognitively normal, 46% had cognitive impairment, no Measurements Physical measures (4‐m walk, 5 chair stands, handgrip, standing balance) scored 0 (unable to...
Background: Gantenerumab is an anti-amyloid-β immunoglobulin G1 monoclonal antibody for subcutaneous (SC) administration. The efficacy and safety of low-dose (105 mg or 225 mg) gantenerumab were investigated in Marguerite RoAD (MR; NCT02051608), a Phase III, double-blind (DB), placebo-controlled study participants with mild Alzheimer’s disease (AD) dementia. Following preplanned futility analysis the SCarlet (NCT01224106), MR was converted into open-label extension (OLE). Objective: DB aimed...
Glioblastoma multiforme (GBM) is characterized by neovascularization, raising the question of whether angiogenic blockade may be a useful therapeutic strategy for this disease. It has been suggested, however, that, to useful, must persistent and at levels sufficient overcome proangiogenic signals from tumor cells. In report, authors tested hypothesis that sustained high concentrations 2 different antiangiogenic proteins, delivered using systemic gene therapy strategy, could inhibit growth...
Abstract Introduction Amyloid‐related imaging abnormalities with edema/effusion (ARIA‐E) are commonly observed anti‐amyloid therapies in Alzheimer's disease. We developed a semi‐mechanistic, silico model to understand the time course of ARIA‐E and its dose dependency. Methods Dynamic statistical analyses data from 112 individuals that experienced open‐label extension SCarlet RoAD (a study gantenerumab participants prodromal disease) Marguerite (as Gantenerumab mild studies were used for...
Abstract INTRODUCTION Anti‐amyloid‐β (Aβ) monoclonal antibodies (mAbs) offer the promise of disease modification and are emerging treatment options in Alzheimer's disease. Anti‐Aβ mAbs require brain magnetic resonance imaging (MRI) examinations to detect anti‐amyloid‐induced amyloid‐related abnormalities (ARIA), important adverse drug reactions associated with some anti‐Aβ currently available United States clinical development. We present a simple rating system for ARIA‐edema (ARIA‐E) that...
Abstract Background Gantenerumab, a human monoclonal antibody targeting aggregated beta‐amyloid (Abeta), is potential disease‐modifying treatment for early (prodromal‐to‐mild) Alzheimer’s disease (AD). SCarlet RoAD (SR) (NCT01224106) and Marguerite (MR) (NCT02051608) were two Phase III trials which assessed the efficacy safety of subcutaneous (SC), low‐dose gantenerumab in participants with prodromal mild AD, respectively, up to 2 years. Following gap period was continued uptitration dose...
Although hypertension (HTN) has been reported as a risk factor for dementia, evidence suggests that this association changes with age and HTN may be protective in the oldest-old. Therefore, we studied whether of all-cause dementia oldest-old varies onset. Participants are from The 90+ Study, an ongoing population-based longitudinal study people aged 90 older who survivors Leisure World Cohort Study (LWCS), established 1981. We estimated onset by combining information LWCS data collected...
Gantenerumab is a fully human anti-amyloid-β (Aβ) immunoglobulin G1 monoclonal antibody for subcutaneous (SC) administration. The efficacy and safety of low-dose (105 mg or 225 mg) gantenerumab were investigated in SCarlet RoAD (SR; NCT01224106), Phase III, double-blind (DB), placebo-controlled study participants with prodromal Alzheimer's disease. Following pre-planned futility analysis, SR was converted into an open-label extension (OLE) study.
Objective: To characterize amyloid reductions among patients with and without amyloid-related imaging abnormalities– edema (ARIA-E) during the open-label extension (OLE) of SCarlet RoAD (SR; NCT01224106) Marguerite (MR; NCT02051608) studies gantenerumab in Alzheimer’s disease (AD). Background: Gantenerumab is a fully human monoclonal antibody currently under evaluation at titrated subcutaneous doses ≤1200mg monthly. has demonstrated high levels reduction on positron emission tomography (PET)...
Vascular diseases in midlife are commonly associated with an increased risk of dementia later life. In contrast, we found that history hypertension the oldest-old was a decreased dementia. Whether this protective association is unique to or if other vascular have similar effect unknown. Here analyze common relation all-cause cohort (90 years and older) participants. Participants from The 90+ Study, ongoing population-based longitudinal study people aged 90 older. At baseline, self-reported...
Abstract Background Vasogenic edema and sulcal effusions detected with magnetic resonance imaging (MRI) are known manageable possible side effects of many anti‐amyloid immunotherapies. Periodic MRI scans severity assessment these findings, as amyloid‐related abnormalities – (ARIA‐E) currently mandated in clinical trials evaluating therapies. Previous studies gantenerumab have used a 60‐point scale (the Barkhof Grand Total Scale [BGTS]), 1 which is effective for research purposes good...